Nanomedical Global Sales to Reach $130.9 Billion in 2016
The market for nanotechnology used in medicine can be broken down into six segments by therapeutic application: cardiovascular, anti-inflammatories, anti-infectives, central nervous system (CNS) products, anticancers, and other applications.
- The cardiovascular segment of the market, worth $4 billion in 2011, is expected to increase at a CAGR of 16.5% to reach $8.6 billion in 2016.
- The anti-inflammatories segment of the market, worth $7.3 billion in 2011, is expected to increase at a CAGR of 15.2% to reach $14.8 billion in 2016.
- The anti-infectives segment was valued at $9.3 billion in 2011 and, by 2016, that value should reach $14.8 billion, a CAGR of 9.7%.
- The CNS products segment was valued at $14 billion in 2011 and, by 2016, that value should reach $29.5 billion, a CAGR of 16.1%.
- The largest segment, comprised of anti-cancers, was worth $28 billion in 2011, and after increasing at a CAGR of 10.8%, should be worth $46.7 billion in 2016.
- The segment made up of other applications was worth $10.2 billion in 2011, and in 2016 should be worth $16.5 billion, a CAGR of 10.1%.
Nanomedicine is already an established market. Unlike some other potential applications of nanotechnology, which are still largely experimental, nanomedicine already has produced a number of significant products in which the nano dimension has made a significant contribution to product effectiveness. Now that aspects of the nanomedicine market are established, it is appropriate to review the technology, see its practical applications so far, evaluate the participating companies, and look to its future.
In the field of nanomedicine research, the United States accounts for one-third of all publications and half of patent filings. A comparison between Europe as a whole and the United States shows that, while Europe is at the forefront of research, the United States leads in the number of patent filings. The strong patenting activity of U.S. scientists and companies indicates a more advanced commercialization status than elsewhere.
This report is designed to satisfy the information needs of a wide variety of individuals involved in the pharmaceutical marketplace, including company senior management executives seeking to base their strategic decisions on the best available information on market forces and trends. It also is aimed, however, at managers and executives in marketing, research, planning and sales departments who need readable, comprehensive, and up-to-date background on the marketplace in which they are operating.